Related Experiment Video

Updated: May 10, 2026

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B

Ping Liu1, Meiyan Qi, Chengbin Ma

  • 1Gynecology Department, Changning Maternity and Infant Health Hospital, Shanghai, China.

FEBS Letters
|June 18, 2013
PubMed

Insights

MicroRNAs regulate gene expression in cancer. This study found let-7a microRNA (miRNA) is down-regulated in endometrial carcinoma (EC) and suppresses cancer cell growth by targeting Aurora-B, offering potential gene therapy applications.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression.
  • Aberrant miRNA expression is implicated in various cancers, including endometrial carcinoma (EC).
  • Understanding specific miRNA roles in EC pathogenesis is crucial for therapeutic development.

Purpose of the Study:

  • To identify differentially expressed miRNAs in endometrial carcinoma (EC) compared to normal tissues.
  • To elucidate the specific role and mechanism of let-7a in EC.
  • To explore the potential of let-7a as a therapeutic agent for EC.

Main Methods:

  • Differential expression analysis of 86 miRNAs in EC tissues versus adjacent normal tissues.
  • Functional assays to assess the impact of let-7a on cancer cell proliferation (HeLa cells).
  • Investigation of let-7a's molecular target, Aurora-B, and its regulatory mechanism.

Main Results:

  • 86 miRNAs showed altered expression levels in EC.
  • let-7a and other miR-let-7 members were significantly down-regulated in EC tissues.
  • let-7a suppressed HeLa cell proliferation by directly targeting and down-regulating Aurora-B protein levels.

Conclusions:

  • let-7a is a tumor-suppressive miRNA in endometrial carcinoma.
  • Down-regulation of let-7a contributes to EC development by allowing Aurora-B overexpression.
  • let-7a holds promise as a potential gene therapy target for endometrial cancer.
Keywords:
Endometrial carcinoma cellLet-7aMicroRNATargeting Aurora-B

More Related Videos

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice07:44

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...